Product image of Menopur (Menotrophin) supplied by GNH India

Menopur

Active Ingredient:
Menotrophin
Origin:
EU

Menopur (Menotrophin)

Menotropin, the active ingredient in Menopur, is a gonadotropin presented as an injectable solution for subcutaneous use. It provides both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity to stimulate ovarian follicular development and estrogen production in women with infertility.

GNH India supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

Manufacturer / TM Owner

Ferring Ireland Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Menopur is a gonadotropin used in reproductive medicine to support follicular growth and ovulation.

  • Induction of ovulation in women with anovulation: promotes the development of a dominant follicle to achieve ovulation.
  • Controlled ovarian stimulation for assisted reproductive technology (IVF): enables the growth of multiple follicles to increase the number of retrievable oocytes.
  • Treatment of hypogonadotropic hypogonadism: replaces deficient endogenous gonadotropins to restore normal ovarian function.

How It Works

  • Menotropin contains purified human follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After subcutaneous injection, the FSH component binds to FSH receptors on ovarian granulosa cells, stimulating follicular growth, while the LH component activates LH receptors on theca cells, promoting androgen production that is aromatized to estrogen. The combined activity enhances follicular maturation and estrogen synthesis, facilitating ovulation and supporting assisted reproductive cycles.

Side Effects

Menopur may be associated with a range of adverse reactions, most of which are related to ovarian stimulation and injection site responses.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the injection site.
  • Abdominal bloating: transient abdominal distension.
  • Headache: mild to moderate intensity.
  • Nausea: occasional feeling of queasiness.
  • Ovarian hyperstimulation syndrome (mild): excessive ovarian response causing fluid shifts.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome (severe): rapid weight gain, shortness of breath, and possible hospitalization.
  • Thromboembolic events: rare clot formation in veins or arteries.
  • Allergic reaction: rash, itching, or anaphylaxis.
  • Multiple pregnancy: increased risk of twins or higher-order gestations.

Precautions & Warnings

When using Menopur, clinicians should consider several safety measures to minimise risks.

  • Patient selection: assess for contraindications such as ovarian cysts or uncontrolled thyroid disease.
  • Monitoring: perform regular ultrasound and estradiol assessments to detect excessive ovarian response.
  • Dose adjustment: modify dosage based on individual response and ovarian reserve.
  • Pregnancy testing: confirm non‑pregnant status before initiating therapy.
  • Storage: Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Menopur may interact with other medications that affect ovarian response or hormone metabolism.

Major Interactions (Avoid)

  • GnRH agonists used for down‑regulation: may blunt the intended ovarian stimulation.
  • High‑dose estrogen therapy: can interfere with follicular development.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: increased risk of ovarian hyperstimulation‑related thrombosis.
  • Thyroid hormone replacement: altered hormone levels may affect response.
  • Corticosteroids: may modify ovarian response and fluid balance.

Frequently Asked Questions

Menopur is a gonadotropin preparation used to induce ovulation in women with anovulation, to provide controlled ovarian stimulation for assisted reproductive technologies such as in‑vitro fertilisation, and to treat hypogonadotropic hypogonadism by replacing deficient follicle‑stimulating and luteinizing hormones.

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After subcutaneous injection, FSH binds to receptors on ovarian granulosa cells to promote follicle growth, while LH activates theca‑cell receptors to stimulate androgen production that is converted to estrogen, together supporting follicular maturation and ovulation.

The dose of Menopur is individualized. A prescribing clinician determines the amount and frequency based on the patient’s ovarian reserve, response to previous cycles, and the specific treatment protocol. Dosing regimens are not standardized and should follow the prescriber’s instructions.

Menopur is intended for use before conception to facilitate ovulation and should not be continued during an established pregnancy. Safety data for use while breastfeeding are limited; therefore, the medication is generally not recommended for nursing mothers unless the benefit outweighs potential risk.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling) and import documentation.

Menopur provides both FSH and LH activity in a single preparation, whereas some alternatives, such as recombinant FSH products, contain only FSH. The combined activity can simplify protocols for patients requiring both hormones, but individual response and cost considerations may influence the choice of therapy.

Menopur should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it may be used for a limited period as indicated in the product label.

Menopur is administered by subcutaneous injection, typically into the abdomen or thigh. The injection technique should follow aseptic guidelines, using a sterile needle and syringe. Patients or healthcare providers receive training on proper reconstitution (if required) and injection procedures.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, shortness of breath, and, in rare cases, thromboembolic events. Prompt monitoring and early intervention are essential to mitigate these complications.

Menopur is contraindicated in women with ovarian cysts, uncontrolled thyroid disease, active ovarian or breast cancer, or known hypersensitivity to menotropin or any excipients. It should also be avoided in patients with severe cardiovascular disease or those at high risk for thromboembolic events.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Menotrophin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT